合并症个体中COVID-19突破感染及住院风险
研究基于Truveta平台2021年1月1日至2022年3月31日完成初始疫苗接种的1,218,630例患者,评估合并症者突破感染及后续住院风险。慢性肾病、慢性肺病、糖尿病、免疫抑制状态患者突破感染比例分别为2.85%、3.42%、2.75%、2.88%,无这四种合并症者为1.46%;四种合并症者突破感染及住院风险均增加。
要点
- 慢性肾病、慢性肺病、糖尿病、免疫抑制者突破感染比例分别为2.85%、3.42%、2.75%、2.88%,无合并症者1.46%。
- 免疫抑制状态和慢性肺病者突破感染风险最高,慢性肾病者突破感染后住院风险最高。
- 多种合并症者突破感染或住院风险高于无合并症者。
核心结论
- 完成初始疫苗接种的四种常见合并症个体突破感染及后续住院风险高于无这些合并症者。
- 免疫抑制状态和慢性肺病者突破感染风险最高,慢性肾病者突破感染后住院风险最高。
- 多种合并症者突破感染或住院风险高于无合并症者。
- 常见合并症个体即使接种疫苗也应保持对感染的警惕。
研究设计与样本
- 研究人群为2021年1月1日至2022年3月31日期间Truveta患者人群中已接种疫苗的患者。
- 建立模型描述从完成初始疫苗接种系列至突破感染的时间,以及突破感染后14天内是否住院。
- 模型调整了年龄、种族、族裔、性别和疫苗接种年月。
- 共纳入1,218,630例完成初始疫苗接种的患者。
主要发现
- 慢性肾病患者突破感染比例为2.85%,慢性肺病为3.42%,糖尿病为2.75%,免疫抑制状态为2.88%。
- 无上述四种合并症人群突破感染比例为1.46%。
- 与无四种合并症者相比,有任何一种合并症者突破感染及后续住院风险增加。
临床怎么用
- 原文结论指出常见合并症个体即使接种疫苗也应保持对感染的警惕。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The successful development of multiple COVID-19 vaccines has led to a global vaccination effort to reduce severe COVID-19 infection and mortality. However, the effectiveness of the COVID-19 vaccines wane over time leading to breakthrough infections where vaccinated individuals experience a COVID-19 infection. Here we estimate the risks of breakthrough infection and subsequent hospitalization in individuals with common comorbidities who had completed an initial vaccination series. METHODS: Our study population included vaccinated patients between January 1, 2021 to March 31, 2022 who are present in the Truveta patient population. Models were developed to describe 1) time from completing primary vaccination series till breakthrough infection; and 2) if a patient was hospitalized within 14 days of breakthrough infection. We adjusted for age, race, ethnicity, sex, and year-month of vaccination. RESULTS: Of 1,218,630 patients in the Truveta Platform who had completed an initial vaccination sequence between January 1, 2021 and March 31, 2022, 2.85, 3.42, 2.75, and 2.88 percent of patients with CKD, chronic lung disease, diabetes, or are in an immunocompromised state experienced breakthrough infection, respectively, compared to 1.46 percent of the population without any of these four comorbidities. We found an increased risk of breakthrough infection and subsequent hospitalization in individuals with any of the four comorbidities when compared to individuals without these four comorbidities. CONCLUSIONS: Vaccinated individuals with any of the studied comorbidities experienced an increased risk of breakthrough COVID-19 infection and subsequent hospitalizations compared to the people without any of the studied comorbidities. Individuals with immunocompromising conditions and chronic lung disease were most at risk of breakthrough infection, while people with CKD were most at risk of hospitalization following breakthrough infection. Patients with multiple comorbidities have an even greater risk of breakthrough infection or hospitalization compared to patients with none of the studied comorbidities. Individuals with common comorbidities should remain vigilant against infection even if vaccinated.
引用
- Smits PD, Gratzl S, Simonov M, et al. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023. PMID: 36803895. doi:10.1016/j.vaccine.2023.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。